[A20-115] Olaparib (adenocarcinoma of the pancreas) - Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2021
Project no.:
A20-115
Commission:
Commission awarded on 03.12.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
Hint of lesser benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-56 | Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-57 | Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-36 | Olaparib (ovarian, fallopian tube, peritoneal cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G15-05 | Olaparib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A20-111 | Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-106 | Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |